Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Al18F-NOTA-LM3 vs 68Ga-DOTATATE PET/CT in PPGL
NCT07288931Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of Al18F-NOTA-LM3 in pheochromocytoma and Paraganglioma (PGL), sponsored by Peking Union Medical College Hospital. Primary endpoint: Tumor Detection Rate at 6 months. Started Aug 2024; status: recruiting.
02
Drugs
Al18F-NOTA-LM3
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT07288931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07288931.